Medicinova, Inc. - MNOV STOCK NEWS

MediciNova, Inc. has initiated a Phase 2 clinical trial for MN-001 (tipelukast) targeting non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), and hypertriglyceridemia. The trial includes approximately 40 patients aged 21 to 75, randomized to receive either MN-001 or a placebo for 24 weeks. Co-primary endpoints focus on changes in liver fat content and fasting serum triglycerides. Successful trial results may lead to pivotal Phase 3 trials aimed at supporting a New Drug Application (NDA) for MN-001.

MediciNova, a biopharmaceutical company listed on NASDAQ (MNOV), announced the start of a first-in-human clinical study for a new injectable formulation of MN-166 (ibudilast). This formulation aims to provide healthcare providers with more options for administering MN-166, especially in acute settings and precise injection locations. MN-166 has potential applications in treating various diseases, including ALS and multiple sclerosis. The company has a robust pipeline with several late-stage programs, indicating a strong commitment to advancing innovative therapies.

MediciNova announced a contract modification with BARDA to repurpose MN-166 (ibudilast) as a potential treatment for chlorine gas-induced lung damage, extending the project until March 2023. BARDA previously funded proof-of-concept studies for MN-166 as part of their ReDIRECT program, aiming to develop medical countermeasures against chemical threats. MN-166, a small molecule inhibiting inflammatory cytokines, is also in late-stage development for various neurodegenerative diseases and other conditions.

MediciNova, Inc. (MNOV) announced a research collaboration with Juntendo University to study the effects of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome. Led by Dr. Takashi Mitsui, the research aims to deepen understanding of MN-001's mechanisms, which have shown benefits in reducing triglycerides and improving lipid profiles in previous clinical trials, particularly for patients with type 2 diabetes. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, with MN-001 being a key component in their clinical pipeline.

MediciNova announced positive results from its Phase 2 clinical trial of MN-166 (ibudilast) in COVID-19 patients at risk for acute respiratory distress syndrome (ARDS). The trial showed significant improvements in key endpoints: 71% of patients in the MN-166 group were free of respiratory failure at Day 7 compared to 35% in the placebo group (p=0.02). Additionally, 65% of MN-166 patients were discharged by Day 7 versus 29% in the placebo group (p=0.02). The results suggest MN-166’s potential efficacy in treating ARDS, addressing a significant medical need amidst high mortality rates in affected patients.

MediciNova has announced that executives Yuichi Iwaki and Geoffrey O'Brien will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 1:00 p.m. ET. This discussion will focus on the development of MN-166 (ibudilast), a compound targeting neurological conditions, including ALS and progressive MS. MN-166 is in late-stage clinical trials for various neurodegenerative diseases and is also being assessed for acute respiratory distress syndrome (ARDS) risk.

MediciNova, Inc. (NASDAQ: MNOV) announced the publication of research demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) model. The study, published in Molecular Cancer Research, revealed that MN-166 significantly reduced UM cell migration and metastasis in mice, emphasizing its potential as an adjuvant therapy for UM patients. The research identified macrophage migration inhibitory factor (MIF) as a key target, suggesting that MIF inhibition through MN-166 could address critical needs in metastatic cancer treatment.

MediciNova, a biopharmaceutical company traded as MNOV, announced the completion of patient enrollment in a Phase 2 clinical trial for MN-166 (ibudilast) targeting hospitalized COVID-19 patients at risk for acute respiratory distress syndrome (ARDS). The trial, which involved administering MN-166 or a placebo to subjects over 7 days, aims to assess its efficacy in preventing respiratory failure. Top-line results will be reported following data cleaning. MN-166 is also in late-stage development for other conditions like ALS and multiple sclerosis.

MediciNova, Inc. announced the FDA's completion of its review for a Phase 2 trial of MN-001 (tipelukast), aimed at treating non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM), and hypertriglyceridemia. This trial follows promising results from a prior study where MN-001 successfully reduced serum triglycerides and improved lipid profiles, particularly in T2DM patients. The upcoming study will evaluate liver fat content and serum lipids, with full funding from MediciNova.